Nature CommunicationsCancer BiologyPeer-reviewed journal article
Activating p53Y220C with a Mutant-Specific Small Molecule
Xijun Zhu, Woong Sub ByuniD, Dominika Ewa Pieńkowska, Kha The NguyeniD, Mengxiong WangiD, Sabin A. NettlesiD, Sai P. GourisankariD, Nick A. PhillipsiD, Jan GerhartziD, Qixiang GengiD, Tian QiuiD, Jianing ZhongiD, Zixuan JiangiD, Roman C. SarottiD, Stephen M. HinshawiD, Tinghu ZhangiD, Laura Donatella AttardiiD, Radosław P. NowakiD, Nathanael S. GrayiD
- Citations
- 5
- FWCI
- 10.29
- Field percentile
- top 2%
Abstract
TP53 is the most commonly mutated gene in cancer, but it remains recalcitrant to clinically meaningful therapeutic reactivation. We present here the discovery and characterization of a small molecule chemical inducer of proximity that activates mutant p53. We named this compound TRanscriptional Activator of p53 (TRAP-1) due to its ability to engage mutant p53 and BRD4 in a ternary complex, which potently activates mutant p53 and triggers robust p53 target gene transcription. Treatment of p53Y220C expressing pancreatic cell lines with TRAP-1 results in rapid upregulation of p21 and other p53 target genes and inhibits the growth of p53Y220C-expressing cell lines. Negative control compounds that are unable to form a ternary complex do not have these effects, demonstrating the necessity of chemically induced proximity for the observed pharmacology. This approach to activating mutant p53 highlights how chemically induced proximity can be used to restore the functions of tumor suppressor proteins that have been inactivated by mutation in cancer.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- p53Y220C-BET-bifunctionals (tPRIMEs) drive p53Y220C-mutant cancer cells into apoptosis
Charlotte Kelley, Jae Young Ahn, … Alexandra B. Lantermann·bioRxiv·Aug 13, 2025
- p53 protein abundance is a therapeutic window across TP53 mutant cancers and is targetable with proximity inducing small molecules
Ananthan Sadagopan, Maximilian Carson, … William J. Gibson·Nature Chemical BiologyPeer-reviewed·Nov 3, 2025
- APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Q. Zhang, V. J. N. Bykov, … J. Zawacka-Pankau·bioRxiv·Nov 5, 2017
- Activation of TAp73 and inhibition of thioredoxin reductase for improved cancer therapy in TP53 mutant pancreatic tumors
P. Acedo, A. Fernandes, J. Zawacka-Pankau·bioRxiv·Sep 4, 2018
- Novel allosteric mechanism of p53 activation by small molecules for targeted anticancer therapy
J. Zawacka-Pankau, V. V. Grinkevich, … G. Selivanova·bioRxiv·Dec 7, 2018
- Activation of Multiple Signalling Pathways by P152Lp53 Mutant Reveals New Gain-of-function Implicating Tumorigenesis